"This week in Other Barks & Bites: the European Union Intellectual Property Office announces that it will host its first two-day Copyright Conference in November; the D.C. Circuit finds that Shira Perlmutter showed a likelihood of irreparable harm in granting injunctive relief allowing her to temporarily resume her role as Register of Copyrights; Novartis becomes the latest pharmaceutical company to lose constitutional challenges to the IRA Drug Price Negotiation"
"Novartis is Latest Pharma Company to Lose Medicare Negotiation Challenge at Third Circuit - On Thursday, September 11, the U.S. Court of Appeals for the Third Circuit affirmed the District of New Jersey's summary judgment ruling rejecting several constitutional claims raised by Novartis Pharmaceuticals against the Drug Price Negotiation Program established by the Inflation Reduction Act (IRA), finding that Novartis' participation in t"
Bites denotes substantive news and Barks denotes peripheral items. IPWatchdog invites dog photo submissions to [email protected] for inclusion on the IPWatchdog Dog Wall. The European Union Intellectual Property Office will host its first two-day Copyright Conference in November. The D.C. Circuit found Shira Perlmutter showed a likelihood of irreparable harm and granted injunctive relief to temporarily resume her role as Register of Copyrights. The Third Circuit affirmed the District of New Jersey's summary judgment rejecting several constitutional claims by Novartis against the IRA Drug Price Negotiation Program. Microsoft agreed to unbundle Teams to avoid EU antitrust fines. Commerce Secretary Howard Lutnick expressed intent to recoup federal investments in university IP. The Second Circuit removed a footnote limiting Grokster-based challenges to Vimeo. Twenty One Pilots sued Temu over counterfeit merchandise. Sandoz and Regeneron announced a settlement ending litigation over Sandoz's FDA-approved biosimilar of Eylea.
Read at IPWatchdog.com | Patents & Intellectual Property Law
Unable to calculate read time
Collection
[
|
...
]